Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Current Assets (2016 - 2025)

Coherus Oncology's Current Assets history spans 13 years, with the latest figure at $206.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 39.49% year-over-year to $206.7 million; the TTM value through Dec 2025 reached $206.7 million, down 39.49%, while the annual FY2025 figure was $206.7 million, 39.49% down from the prior year.
  • Current Assets for Q4 2025 was $206.7 million at Coherus Oncology, down from $461.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $673.0 million in Q3 2021 and bottomed at $206.7 million in Q4 2025.
  • The 5-year median for Current Assets is $447.5 million (2022), against an average of $460.8 million.
  • The largest annual shift saw Current Assets surged 98.62% in 2024 before it plummeted 50.57% in 2025.
  • A 5-year view of Current Assets shows it stood at $602.3 million in 2021, then tumbled by 36.71% to $381.2 million in 2022, then rose by 24.76% to $475.6 million in 2023, then decreased by 28.18% to $341.6 million in 2024, then crashed by 39.49% to $206.7 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Current Assets are $206.7 million (Q4 2025), $461.0 million (Q3 2025), and $380.2 million (Q2 2025).